Skip to content

rTMS Therapy for Primary Orthostatic Tremor

rTMS Therapy for Primary Orthostatic Tremor: A Novel Treatment Approach

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02441985
Enrollment
10
Registered
2015-05-12
Start date
2015-08-31
Completion date
2019-01-08
Last updated
2025-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Orthostatic Tremor

Keywords

Primary orthostatic tremor

Brief summary

Primary orthostatic tremor(POT) is a rare progressive functionally disabling tremor disorder. The characteristic features of POT are symptoms of unsteadiness in legs reported by patients when they are standing and improvement of symptoms upon walking and sitting. Due to the limited success of other treatment options there is a clear merit in continuing efforts to explore and investigate novel treatment modalities. Transcranial magnetic stimulation (TMS) is a well-established physiological tool to understand brain function. When repetitious TMS pulses are delivered to a specific target at predefined stimulation parameters, it is referred to as rTMS therapy.The investigators propose a novel approach to investigate the clinical and physiological effects of low frequency rTMS therapy in POT. The overarching hypothesis of this study is that low frequency rTMS therapy delivered to the cerebellum will modulate the cerebellar excitability and result in clinical improvements.In order to determine the physiological effects related to rTMS, the tremor physiology will also be recorded with surface electromyography (EMG). The investigator will also record the changes in cerebellum excitability in response to rTMS using cerebello-cortical inhibition (CBI), a well-established TMS parameter.

Detailed description

POT tremors recorded on surface electromyography (EMG) reveal distinct high frequency bursts of 13-18 Hz tremors in the leg muscles. POT was first described in 1984 at the University of Florida. Since then several clinical descriptions have been published however despite this knowledge for thirty years, treatment opportunities for POT have remained poor. Several medications have been tried, but the results have been disappointing. Thalamic deep brain stimulation (DBS) surgery, which is an invasive therapy approved by the FDA for treatment of essential tremor, was recently investigated in POT but the early results have only been partially successful. In clinical descriptions, POT has been observed to be associated with clinical features of cerebellar dysfunction such as dysmetria and gait ataxia. Positron emission tomography (PET) imaging has shown an increased activation of bilateral cerebellum related either to a mismatch between the peripheral afferent and the cerebellar efferent traffic or to a primary disorder of the cerebellum. MRI study has confirmed a cerebellar atrophy in POT and finally transcranial magnetic stimulation (TMS), has shown POT can be reset by stimulation of the cerebellum. The primary goal of this study is to test the efficacy of low frequency rTMS therapy in POT. The first aim of the study is to determine the clinical impact of 1-Hz rTMS therapy in POT when delivered to the cerebellum. This impact will be evaluated by the clinical scoring of leg tremors in standing posture, and the functional assessment of gait mobility. The second aim of this study is to determine the physiological effects of 1-Hz rTMS therapy in POT when delivered to the cerebellum. The investigator will determine the effects on the amplitude and frequency of tremors recorded with surface EMG. They will also determine the effects on the cerebello-cortical inhibition measured with TMS. Comparisons will be drawn between before rTMS therapy, immediately or +5 minutes after and 60+ minutes after assessments to determine the time course of effects. In this application, subjects with POT will be enrolled based on clinical history, physical exam and a 13-18 Hz tremor recorded on the surface EMG in accordance with the Consensus Statement of the Movement Disorder Society. Data will be presented as mean (SD) unless otherwise indicated. For each of the outcome variables, the statistical analyst will conduct a mixed model analysis using time and stimulation arm as repeated factors adjusted for baseline values, and subjects as the random factor.

Interventions

Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.

Same procedure as real rTMS without stimulating the cerebral cortex.

OTHERFullerton Advanced Balance (FAB) Scale

All participants will receive a clinical assessment of balance ability and fall risk.

OTHERTimed Up & Go Test (TUG) test

All participants will receive a clinical assessment of basic mobility skills by using the TUG test.

OTHER10m walk test

All participants will receive a clinical assessment of walking speed by using the walk test.

OTHERTremor electrophysiology

All participant tremors will by analyzed using an EMG system

All participants will have a measure of the cerebellar-brain inhibition (CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.

Sponsors

National Organization for Rare Disorders
CollaboratorOTHER
Neuronetics
CollaboratorOTHER
University of Florida
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Potential participants will be diagnosed with Primary orthostatic tremor (POT) and be recruited through IRB approved database maintained by the Movement Disorders Center

Exclusion criteria

* Pregnancy * Active seizure disorder * Significant cognitive impairment * Presence of a metallic body such as pacemaker, implants, prosthesis,artificial limb or joint, shunt, metal rods and hearing aid

Design outcomes

Primary

MeasureTime frameDescription
Change in Fullerton Advanced Balance (FAB) Scale Total Score After rTMSPre- to Post-Intervention, on average 3 hoursThe Fullerton Advanced Balance (FAB) Scale is a clinical assessment of balance ability and fall risk. Participants complete 10 physical activity challenges while observed, and their performance is rated on a 0-4 scale, where a higher score a greater ability to balance. Each item is then summed to generate a Total Score, ranging from 0-40, where a higher total score indicates greater overall balance and lower likelihood of fall risk. The reported measure is the change in the FAB Total Score from before and after, where a positive value implies improvement in balance, a negative value indicates a worsening of balance, and 0 indicates no change.

Other

MeasureTime frameDescription
Standing DurationPre- to Post-Intervention, on average 3 hours apartParticipants were asked to stand for as long as they could. Their standing duration was video recorded and timed in seconds. The measure reported is the change in standing time from before to after the rTMS intervention, where a positive value indicates an improvement in standing duration, a negative value indicates a worsening of standing duration, and 0 indicates no change.
Timed Up & Go Test (TUG) TestPre- to Post-InterventionThe TUG is a mobility test that is used to measure the basic mobility skills and gait speed of people who have neurological conditions. It includes a sit-to-stand component as well as walking 3 m, turning, and returning to the chair. People perform these tasks using regular footwear and customary walking aids. The measured outcome is the time in seconds to complete the entire sequence. For the outcome assessment the test will be videotaped and scored by a blind rater. We calculated the change between two time points (pre intervention value minus post intervention value)

Countries

United States

Participant flow

Pre-assignment details

10/10 participants who expressed interest in research were randomized

Participants by arm

ArmCount
Real rTMS Stimulation First, Then Sham rTMS Stimulation
Participants freceived 900 pulse of real rTMS
5
Sham rTMS Stimulation First, Then Real rTMS Stimulation
Participants received 900 pulse of sham rTMS
5
Total10

Baseline characteristics

CharacteristicReal rTMS Stimulation First, Then Sham rTMS StimulationSham rTMS Stimulation First, Then Real rTMS StimulationTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
3 Participants3 Participants6 Participants
Age, Categorical
Between 18 and 65 years
2 Participants2 Participants4 Participants
Age, Continuous71.3 years
STANDARD_DEVIATION 8.3
71.3 years
STANDARD_DEVIATION 8.3
71.3 years
STANDARD_DEVIATION 8.3
Disease Duration14.7 years
STANDARD_DEVIATION 10.7
14.7 years
STANDARD_DEVIATION 10.7
14.7 years
STANDARD_DEVIATION 10.7
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
5 Participants5 Participants10 Participants
Sex: Female, Male
Female
3 Participants3 Participants6 Participants
Sex: Female, Male
Male
2 Participants2 Participants4 Participants
Standing Duration97 seconds
STANDARD_DEVIATION 74
97 seconds
STANDARD_DEVIATION 74
97 seconds
STANDARD_DEVIATION 74
Tremor Frequency15.5 Hz
STANDARD_DEVIATION 0.7
15.5 Hz
STANDARD_DEVIATION 0.7
15.5 Hz
STANDARD_DEVIATION 0.7

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 100 / 10
other
Total, other adverse events
0 / 100 / 10
serious
Total, serious adverse events
0 / 100 / 10

Outcome results

Primary

Change in Fullerton Advanced Balance (FAB) Scale Total Score After rTMS

The Fullerton Advanced Balance (FAB) Scale is a clinical assessment of balance ability and fall risk. Participants complete 10 physical activity challenges while observed, and their performance is rated on a 0-4 scale, where a higher score a greater ability to balance. Each item is then summed to generate a Total Score, ranging from 0-40, where a higher total score indicates greater overall balance and lower likelihood of fall risk. The reported measure is the change in the FAB Total Score from before and after, where a positive value implies improvement in balance, a negative value indicates a worsening of balance, and 0 indicates no change.

Time frame: Pre- to Post-Intervention, on average 3 hours

ArmMeasureValue (MEAN)Dispersion
Real rTMS StimulationChange in Fullerton Advanced Balance (FAB) Scale Total Score After rTMS2.8 change in score on a scaleStandard Deviation 0.2
Sham rTMS StimulationChange in Fullerton Advanced Balance (FAB) Scale Total Score After rTMS0.9 change in score on a scaleStandard Deviation 0.01
Other Pre-specified

Standing Duration

Participants were asked to stand for as long as they could. Their standing duration was video recorded and timed in seconds. The measure reported is the change in standing time from before to after the rTMS intervention, where a positive value indicates an improvement in standing duration, a negative value indicates a worsening of standing duration, and 0 indicates no change.

Time frame: Pre- to Post-Intervention, on average 3 hours apart

ArmMeasureValue (MEAN)Dispersion
Real rTMS StimulationStanding Duration126 secondsStandard Deviation 82.2
Sham rTMS StimulationStanding Duration-6.7 secondsStandard Deviation 29.3
Other Pre-specified

Timed Up & Go Test (TUG) Test

The TUG is a mobility test that is used to measure the basic mobility skills and gait speed of people who have neurological conditions. It includes a sit-to-stand component as well as walking 3 m, turning, and returning to the chair. People perform these tasks using regular footwear and customary walking aids. The measured outcome is the time in seconds to complete the entire sequence. For the outcome assessment the test will be videotaped and scored by a blind rater. We calculated the change between two time points (pre intervention value minus post intervention value)

Time frame: Pre- to Post-Intervention

ArmMeasureValue (MEAN)Dispersion
Real rTMS StimulationTimed Up & Go Test (TUG) Test13 secondsStandard Deviation 1.5
Sham rTMS StimulationTimed Up & Go Test (TUG) Test12 secondsStandard Deviation 1.6

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026